Инфекции и системные васкулиты
https://doi.org/10.14412/1996-7012-2022-5-75-81
Аннотация
Инфекции и системные васкулиты (СВ) характеризуются взаимным влиянием, что повышает риск возникновения, усугубляет течение и исход заболевания. В обзоре рассматриваются вопросы, касающиеся как триггерной роли инфекций в развитии СВ, так и коморбидных инфекций (КИ), осложняющих течение заболевания. Распознавание инфекционной этиологии СВ имеет большое значение, поскольку требует всестороннего обследования и при необходимости раннего и полноценного этиотропного лечения. Поскольку СВ per se и применение как индукционной, так и поддерживающей иммуносупрессивной терапии являются значимыми факторами риска вторичных КИ, особое внимание необходимо уделять предупреждению последних, включая вакцинопрофилактику, в первую очередь против гриппа и пневмококковой инфекции.
Об авторах
Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Борис Сергеевич Белов
115522, Москва, Каширское шоссе, 34А
О. Н. Егорова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Г. М. Тарасова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Н. В. Муравьева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Насонов ЕЛ, Баранов АА, Шилкина НП. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. 616 с.
2. Theofilis P, Vordoni A, Koukoulaki M, et al. Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatol Int. 2022 May;42(5): 759-70. doi: 10.1007/s00296-022-05100-9. Epub 2022 Feb 14.
3. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4;335(1):16-20. doi: 10.1056/NEJM199607043350103.
4. Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2021 Aug 2;60(8): 3553-64. doi: 10.1093/rheumatology/keab267.
5. Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022 Jun 23. doi: 10.1007/s10067-022-06240-w. Online ahead of print.
6. Huan G, Yang G, Xiao-Yu Q, et al. Antineutrophil cytoplasmic antibodies in Chinese patients with tuberculosis. Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):475-8. doi: 10.1590/0037-8682-0400-2017.
7. Choi H, Park YB, Song J, Lee SW. Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. Z Rheumatol. 2021 Apr 27. doi: 10.1007/s00393-021-00998-1. Online ahead of print.
8. Söderberg D, Segelmark M. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol. 2016 Jun 30;7:256. doi: 10.3389/fimmu.2016.00256.
9. Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel). 2016 Mar;1(4): 205-15. doi: 10.1159/000442323. Epub 2015 Dec 3.
10. Lizarraga KJ, Florindez JA, Daftarian P, et al. Anti-GBM disease and ANCA during dengue infection. Clin Nephrol. 2015 Feb; 83(2):104-10. doi: 10.5414/CN108217.
11. Asano S, Mizuno S, Okachi S, et al. Antineutrophil Cytoplasmic Antibody-associated Vasculitis Superimposed on Infection-related Glomerulonephritis Secondary to Pulmonary Mycobacterium avium Complex Infection. Intern Med. 2016;55(17):2439-45. doi: 10.2169/internalmedicine.55.6588. Epub 2016 Sep 1.
12. Addy C, Doran G, Jones AL, et al. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med. 2018 Nov 19;18(1):170. doi: 10.1186/s12890-018-0732-3.
13. Hashimoto S, Aizawa T, Watanabe S, et al. Osteomyelitis-related glomerulonephritis with myeloperoxidase-antineutrophil cytoplasmic antibody positivity. Pediatr Int. 2020 Feb; 62(2):236-8. doi: 10.1111/ped.14080.
14. Sugino H, Sawada Y, Nakamura M. IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int J Mol Sci. 2021 Jul 14;22(14):7538. doi: 10.3390/ijms22147538.
15. Абдурахманов ДТ, Розина ТП, Новиков ПИ. HBV-ассоциированный узелковый полиартериит. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2012;(3):67-71.
16. Семенкова ЕН. Системные некротизирующие васкулиты. Москва: Русский врач; 2001. 96 с.
17. Игнатова ТМ, Козловская ЛВ, Гордовская НБ, и др. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С: 20-летний опыт лечения. Терапевтический архив. 2017:(5):45-62.
18. Vega LE, Espinoza LR. Vasculitides in HIV Infection. Curr Rheumatol Rep. 2020 Aug 26;22(10):60. doi: 10.1007/s11926-020-00945-0.
19. Vega LE, Espinoza LR. Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in the pre- and post-HAART eras. Clin Rheumatol. 2020 Sep; 39(9):2515-22. doi: 10.1007/s10067-020-05082-8. Epub 2020 Apr 15.
20. Giryes S, Bragazzi NL, Bridgewood C, et al. COVID-19 Vasculitis and vasculopathyDistinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Semin Immunopathol. 2022 May;44(3):375-90. doi: 10.1007/s00281-022-00928-6. Epub 2022 Apr 12.
21. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020 Jun; 46(6):1105-8. doi: 10.1007/s00134-020-06059-6. Epub 2020 Apr 28.
22. Брегель ЛВ, Костик ММ, Фелль ЛЗ и др. Болезнь Кавасаки и мультисистемный воспалительный синдром при инфекции COVID-19 у детей. Педиатрия им. Г.Н. Сперанского. 2020;(6):209-19.
23. Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open. 2021 Sep 1;4(9):e2126456. doi: 10.1001/jamanetworkopen.2021.26456.
24. Fabi M, Filice E, Biagi C, et al. Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area. Viruses. 2021 Oct 7;13(10): 2022. doi: 10.3390/v13102022.
25. Sollini M, Ciccarelli M, Cecconi M, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/ CT study. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1460-6. doi: 10.1007/s00259-020-05084-3.
26. Morris D, Patel K, Rahimi O, et al. ANCA vasculitis: A manifestation of PostCovid-19 Syndrome. Respir Med Case Rep. 2021;34:101549. doi: 10.1016/j.rmcr.2021.101549. Epub 2021 Nov 11.
27. Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Nov; 3(11):e743-e744. doi: 10.1016/S2665-9913(21)00309-X.
28. Nappi E, De Santis M, Paoletti G, et al. New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine. Vaccines (Basel). 2022 May 3;10(5):716. doi: 10.3390/vaccines10050716.
29. Al-Yafeai Z, Horn BJM, Terraccaine W, et al. A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination. Cureus. 2022 Mar 14;14(3):e23162. doi: 10.7759/cureus.23162.
30. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011 Jan;63(1):257-66. doi: 10.1002/art.27763.
31. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012 Nov;64(11):3770-8. doi: 10.1002/art.34584.
32. Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi: 10.1136/ard.2008.088302.
33. Aasarød K, Iversen BM, Hammerstrøm J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant. 2000 May;15(5): 611-8. doi: 10.1093/ndt/15.5.611.
34. Bligny D, Mahr A, Toumelin PL, et al. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004 Feb 15;51(1):83-91. doi: 10.1002/art.20082.
35. Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi: 10.1186/s12882-018-0933-2.
36. Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi: 10.1111/eci.12410.
37. Jung M, Barra L. Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a metaanalysis. Clin Exp Rheumatol. 2018 Mar-Apr; 36 Suppl 111(2):129-34.
38. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133
39. Segelmark L, Flores-Suarez L, Mohammad A. Severe infections in patients with ANCA-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2021 Dec 24;61(1):205-12. doi: 10.1093/rheumatology/keab293.
40. Odler B, Windpessl M, Krall M, et al. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. Front Immunol. 2021 Oct 29;12:760708. doi: 10.3389/fimmu.2021.760708. eCollection 2021.
41. Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Feb;60(2):97-105. doi: 10.5414/CP204053.
42. Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-87. doi: 10.1001/jama.2021.6615.
43. Godeau B, Mainardi JL, Roudot-Thoraval F, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis. 1995 Dec; 54(12):991-4.
44. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener’s granulomatosis. Am J Respir Crit Care Med. 1995 Mar;151 (3 Pt 1):795-9. doi: 10.1164/ajrccm/151.3_Pt_1.795.
45. Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systemic review. Clin Rheumatol. 2007 May;26(5): 663-70. doi: 10.1007/s10067-006-0441-9. Epub 2006 Dec 21.
46. Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014 Dec;127(12):1242.e11- 7. doi: 10.1016/j.amjmed.2014.07.010. Epub 2014 Jul 21.
47. Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006 Jun;12(3):114-7. doi: 10.1097/01.rhu.0000221794.24431.36.
48. Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014 Dec; 34(12):1765-71. doi: 10.1007/s00296-014-3073-4. Epub 2014 Jun 20.
49. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener’s granulomatosis. Arthritis Rheum. 1997 Dec;40(12):2187-98. doi: 10.1002/art.1780401213.
50. Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.
51. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1;369(5):417-27. doi: 10.1056/NEJMoa1213277.
52. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.
53. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-83. doi: 10.1002/art.41773. Epub 2021 Jul 8.
54. Chung JB, Armstrong K, Schwartz S, et al. Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000 Aug;43(8):1841-8. doi: 10.1002/1529-0131(200008)43:83.0.CO;2-Q.
55. Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-e864. doi: 10.1016/S2665-9913(21)00316-7. Epub 2021 Nov 5.
56. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.
57. David R, Hanna P, Lee K, Ritchie A. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients. Nephrology (Carlton). 2022 Jan; 27(1):109-10. doi: 10.1111/nep.13993. Epub 2021 Nov 9.
58. Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021 Oct 28;9(10): e05032. doi: 10.1002/ccr3.5032. eCollection 2021 Oct.
59. Dharia T, Venkatachalam S, Baker JF, et al. Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care Res (Hoboken). 2022 May;74(5):733-40. doi: 10.1002/acr.24837.
60. Chen YX, Yu HJ, Zhang W, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodiesassociated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008; 31(5):343-9. doi: 10.1159/000165117. Epub 2008 Oct 23.
61. Itabashi M, Takei T, Yabuki Y, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115(1):c21-7. doi: 10.1159/000286346. Epub 2010 Feb 19.
62. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. 2011 Mar;70(3):488-94. doi: 10.1136/ard.2010.137778.
Рецензия
Для цитирования:
Белов БС, Егорова ОН, Тарасова ГМ, Муравьева НВ. Инфекции и системные васкулиты. Современная ревматология. 2022;16(5):75-81. https://doi.org/10.14412/1996-7012-2022-5-75-81
For citation:
Belov BS, Egorova ON, Tarasova GM, Muravieva NV. Infections and systemic vasculitis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(5):75-81. (In Russ.) https://doi.org/10.14412/1996-7012-2022-5-75-81
Просмотров:
618
Послать статью по эл. почте 